RATIONALE: Misuse or dislike of nicotine replacement treatments (NRTs) undermines their effectiveness. Brief testing among NRTs could allow tailoring by preference to improve outcome. OBJECTIVE: To test initial reactions/preferences to NRTs in a single session crossover design with guided use. METHODS: Smokers were offered two doses of three NRTs: gum (2 and 4 mg), inhaler, and nasal spray (NNS) in a 5-h test with proper use enforced. Subjects rated each NRT and ranked among NRTs on use variables and preferences. RESULTS:Gum was ranked over inhaler and NNS for "ease of use," "safety" and "prefer in public." Four-milligram gum was rated higher than 2 mg on several variables. With experience, "ease of use" and "liking" improved for gum. Both inhaler and NNS ranked low on considering "use >3 months" vs gum. Dislike of NRT was reflected in refusal of second doses. For those testing all doses (n=9), inhaler ranked last on "relief of withdrawal," "choose under stress," and "choice to help quit." Craving and withdrawal were relieved over time with any NRT use. CONCLUSIONS: Sampling of treatments can identify reactions key to initial compliance with these NRTs.
RCT Entities:
RATIONALE: Misuse or dislike of nicotine replacement treatments (NRTs) undermines their effectiveness. Brief testing among NRTs could allow tailoring by preference to improve outcome. OBJECTIVE: To test initial reactions/preferences to NRTs in a single session crossover design with guided use. METHODS: Smokers were offered two doses of three NRTs: gum (2 and 4 mg), inhaler, and nasal spray (NNS) in a 5-h test with proper use enforced. Subjects rated each NRT and ranked among NRTs on use variables and preferences. RESULTS: Gum was ranked over inhaler and NNS for "ease of use," "safety" and "prefer in public." Four-milligram gum was rated higher than 2 mg on several variables. With experience, "ease of use" and "liking" improved for gum. Both inhaler and NNS ranked low on considering "use >3 months" vs gum. Dislike of NRT was reflected in refusal of second doses. For those testing all doses (n=9), inhaler ranked last on "relief of withdrawal," "choose under stress," and "choice to help quit." Craving and withdrawal were relieved over time with any NRT use. CONCLUSIONS: Sampling of treatments can identify reactions key to initial compliance with these NRTs.
Authors: Saul Shiffman; Carolyn M Dresler; Peter Hajek; Simon J A Gilburt; Darren A Targett; Kenneth R Strahs Journal: Arch Intern Med Date: 2002-06-10
Authors: Nina G Schneider; Richard E Olmstead; Mitchell Nides; Freny Vaghaiwalla Mody; Pamela Otte-Colquette; Kim Doan; Shilpan Patel Journal: Am J Health Behav Date: 2004 Jan-Feb
Authors: Raymond Niaura; Michael Sayette; Saul Shiffman; Elbert D Glover; Mitch Nides; Morris Shelanski; William Shadel; Randy Koslo; Bruce Robbins; Jim Sorrentino Journal: Addiction Date: 2005-11 Impact factor: 6.526
Authors: S J Leischow; S N Valente; A L Hill; P S Otte; M Aickin; T Holden; E Kligman; G Cook Journal: Exp Clin Psychopharmacol Date: 1997-02 Impact factor: 3.157
Authors: Jonathan Foulds; Michael Burke; Michael Steinberg; Jill M Williams; Douglas M Ziedonis Journal: Expert Opin Emerg Drugs Date: 2004-05 Impact factor: 4.191
Authors: Nina G Schneider; Margaret A Koury; Chris Cortner; Richard E Olmstead; Neil Hartman; Leonard Kleinman; Andrew Kim; Craig Chaya; David Leaf Journal: Psychopharmacology (Berl) Date: 2006-08-01 Impact factor: 4.530
Authors: Kevin P Jensen; Elise E DeVito; Aryeh I Herman; Gerald W Valentine; Joel Gelernter; Mehmet Sofuoglu Journal: Neuropsychopharmacology Date: 2015-05-07 Impact factor: 7.853
Authors: Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove Journal: Int J Neuropsychopharmacol Date: 2010-10-29 Impact factor: 5.176
Authors: Richard J O'Connor; Kaila J Norton; Maansi Bansal-Travers; Martin C Mahoney; K Michael Cummings; Ron Borland Journal: Harm Reduct J Date: 2011-01-10